» Articles » PMID: 17173035

Molecular Evolution of Antibody Cross-reactivity for Two Subtypes of Type A Botulinum Neurotoxin

Overview
Journal Nat Biotechnol
Specialty Biotechnology
Date 2006 Dec 19
PMID 17173035
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Broadening antibody specificity without compromising affinity should facilitate detection and neutralization of toxin and viral subtypes. We used yeast display and a co-selection strategy to increase cross-reactivity of a single chain (sc) Fv antibody to botulinum neurotoxin type A (BoNT/A). Starting with a scFv that binds the BoNT/A1 subtype with high affinity (136 pM) and the BoNT/A2 subtype with low affinity (109 nM), we increased its affinity for BoNT/A2 1,250-fold, to 87 pM, while maintaining high-affinity binding to BoNT/A1 (115 pM). To find the molecular basis for improved cross-reactivity, we determined the X-ray co-crystal structures of wild-type and cross-reactive antibodies complexed to BoNT/A1 at resolutions up to 2.6 A, and measured the thermodynamic contribution of BoNT/A1 and A2 amino acids to wild-type and cross-reactive antibody binding. The results show how an antibody can be engineered to bind two different antigens despite structural differences in the antigen-antibody interface and may provide a general strategy for tuning antibody specificity and cross-reactivity.

Citing Articles

Engineering affinity-matured variants of an anti-polysialic acid monoclonal antibody with superior cytotoxicity-mediating potency.

Wang W, Bunyatov M, Lopez-Barbosa N, DeLisa M bioRxiv. 2025; .

PMID: 40027839 PMC: 11870402. DOI: 10.1101/2025.02.12.637914.


Selection of Candidate Monoclonal Antibodies for Therapy of Botulinum Toxin Type A Intoxications.

Zeninskaya N, Ryabko A, Marin M, Kombarova T, Shkuratova M, Rogozin M Toxins (Basel). 2024; 16(7).

PMID: 39057924 PMC: 11281656. DOI: 10.3390/toxins16070284.


Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.

Yamagata A, Ito K, Suzuki T, Dohmae N, Terada T, Shirouzu M Nat Commun. 2024; 15(1):3027.

PMID: 38637505 PMC: 11026379. DOI: 10.1038/s41467-024-47322-4.


Presynaptic targeting of botulinum neurotoxin type A requires a tripartite PSG-Syt1-SV2 plasma membrane nanocluster for synaptic vesicle entry.

Joensuu M, Syed P, Saber S, Lanoue V, Wallis T, Rae J EMBO J. 2023; 42(13):e112095.

PMID: 37226896 PMC: 10308369. DOI: 10.15252/embj.2022112095.


Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs.

Teixeira A, DAngelo S, Erasmus M, Leal-Lopes C, Ferrara F, Spector L MAbs. 2022; 14(1):2115200.

PMID: 36068722 PMC: 9467613. DOI: 10.1080/19420862.2022.2115200.